Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 4/20 | 0.66 |
| ▸ | P2RY2 | P41231 | 2/20 | 0.50 |
| ▸ | P2RY4 | P51582 | 2/20 | 0.50 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.50 |
| ▸ | TYMS | P04818 | 4/20 | 0.49 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.47 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.47 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.47 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | TK1 | P04183 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6034461 | 0.90 | DUT (0.66) | DUTP2RY2P2RY4P2RY6TYMS | |
| SCHEMBL15798318 | 0.89 | DUT (0.64) | DUTP2RY2P2RY4P2RY6TYMS | |
| SCHEMBL2056624 | 0.89 | DUT (0.64) | DUTP2RY2P2RY4P2RY6TYMS | |
| SCHEMBL4298071 | 0.89 | DUT (0.64) | DUTP2RY2P2RY4P2RY6TYMS | |
| SCHEMBL13153886 | 0.89 | DUT (0.64) | DUTP2RY2P2RY4P2RY6TYMS | |
| SCHEMBL3716323 | 0.89 | DUT (0.64) | DUTP2RY2P2RY4P2RY6TYMS | |
| SCHEMBL438240 | 0.89 | DUT (0.64) | DUTP2RY2P2RY4P2RY6TYMS | |
| SCHEMBL2009956 | 0.89 | DUT (0.64) | DUTP2RY2P2RY4P2RY6TYMS | |
| SCHEMBL1255927 | 0.89 | DUT (0.64) | DUTP2RY2P2RY4P2RY6TYMS | |
| SCHEMBL26757491 | 0.89 | DUT (0.64) | DUTP2RY2P2RY4P2RY6TYMS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 449 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8629262-B2 | Detection of chromosomal inversions using non-repetitive nucleic acid probes | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2014-01-14 | — | — | US | claimed |
| US-6200257-B1 | Catheter with permeable hydrogel membrane | PROXIMA THERAPEUTICS, INC. | 2001-03-13 | — | — | US | claimed |
| US-20260102450-A1 | COMPOSITION AND FOOD SUPPLEMENTARY FOR SARCOPENIA AND PERIODONTAL DISEASES CONTAINING ALDER AND ELM COMPLEX EXTRACTS AS ACTIVE INGREDIENTS | DR OREGONIN INC (KR) | 2026-04-16 | — | — | US | disclosed |
| EP-3797770-B1 | SOFTGEL CAPSULE COMPRISING APALUTAMIDE | ARAGON PHARMACEUTICALS INC (US) | 2026-02-18 | — | — | EP | disclosed |
| EP-2762558-B1 | METHOD FOR PRODUCING TISSUE AND ORGAN | PUBLIC UNIV CORP YOKOHAMA CITY UNIV (JP) | 2026-01-21 | — | — | EP | disclosed |
| US-12496353-B2 | Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the PI3K-AKT mTOR pathway | SEAGEN INC. (US) | 2025-12-16 | — | — | US | disclosed |
| US-20250319139-A1 | METHODS FOR TREATING NEUROINFLAMMATION | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2025-10-16 | — | — | US | disclosed |
| US-20250270270-A1 | COMPOSITION INCLUDING IL-32 THETA MUTANT AND USE THEREOF | KONKUK UNIVERSITY INDUSTRIAL COOPERATION CORP (KR) | 2025-08-28 | — | — | US | disclosed |
| WO-2025101652-A1 | SELECTIVE MAMMALIAN STERILE 20-LIKE KINASE 1 (MST1) MODULATOR COMPOUNDS AS THERAPEUTICS FOR DIABETES AND LIVER REGENERATION | THE SCRIPPS RESEARCH INSTITUTE (US) | 2025-05-15 | — | — | WO | disclosed |
| US-20250134917-A1 | COMPOSITIONS AND METHODS OF REGENERATING HEART TISSUES WITH AMINOGLYCOSIDES | THE UAB RESEARCH FOUNDATION | 2025-05-01 | — | — | US | disclosed |
| US-20250066864-A1 | METHODS FOR IDENTIFYING ADAR1 INHIBITORS, AND COMPOSITIONS AND METHODS OF USE IN TREATING CANCER | WISTAR INST (US) | 2025-02-27 | — | — | US | disclosed |
| EP-0871475-A2 | INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3 (IGF-BP3) IN TREATMENT OF P53-RELATED TUMORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-10-21 | — | — | EP | disclosed |
| EP-0754187-A4 | GROWTH ARREST HOMEOBOX GENE | UNIV CASE WESTERN RESERVE (US) | 1998-08-05 | — | — | EP | disclosed |
| WO-1997033989-A9 | TRANSGENIC ANIMALS HAVING A DISRUPTED eNOS GENE AND USE THEREOF | — | 1998-04-02 | — | — | WO | disclosed |
| WO-1997033989-A1 | TRANSGENIC ANIMALS HAVING A DISRUPTED eNOS GENE AND USE THEREOF | THE GENERAL HOSPITAL CORPORATION (US) | 1997-09-18 | — | — | WO | disclosed |
| WO-1997026270-A2 | SYNTHESIS OF METHOXY NUCLEOSIDES AND ENZYMATIC NUCLEIC ACID MOLECULES | RIBOZYME PHARMACEUTICALS, INC. (US) | 1997-07-24 | — | — | WO | disclosed |
| WO-1997009998-A2 | INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3 (IGF-BP3) IN TREATMENT OF P53-RELATED TUMORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1997-03-20 | — | — | WO | disclosed |
| EP-0754187-A1 | GROWTH ARREST HOMEOBOX GENE | CASE WESTERN RESERVE UNIVERSITY (US) | 1997-01-22 | — | — | EP | disclosed |
| WO-1995023161-A1 | GROWTH ARREST HOMEOBOX GENE | CASE WESTERN RESERVE UNIVERSITY (US) | 1995-08-31 | — | — | WO | disclosed |
| WO-1990005789-A1 | IN SITU SUPPRESSION HYBRIDIZATION AND USES THEREFOR | YALE UNIVERSITY (US) | 1990-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12496353-B2 | Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the PI3K-AKT mTOR pathway | MTOR, RICTOR, PIK3R5 | DUT 2612/4885P2RY2 4536/4885P2RY4 4467/4885 |
| US-20260102450-A1 | COMPOSITION AND FOOD SUPPLEMENTARY FOR SARCOPENIA AND PERIODONTAL DISEASES CONTAINING ALDER AND ELM COMPLEX EXTRACTS AS ACTIVE INGREDIENTS | MYOF, PYGM, MTPN | DUT 3531/4885P2RY2 1241/4885P2RY4 1432/4885 |
| US-20250066864-A1 | METHODS FOR IDENTIFYING ADAR1 INHIBITORS, AND COMPOSITIONS AND METHODS OF USE IN TREATING CANCER | ADA, ADAR, NTPCR | DUT 36/4885P2RY2 823/4885P2RY4 1116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.